The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has approved an additional manufacturing site for the production of the Comirnaty COVID-19 vaccine, developed by Pfizer and BioNTech, and an additional site for Spikevax, the COVID-19 Vaccine developed by Moderna, in the European Union (EU).
Comirnaty’s site in Saint Rémy sur Avre, France, operated by Delpharm, will manufacture finished product. EMA states that the site will provide up to 51 million additional doses in 2021. EMA has also approved a new manufacturing line at BioNTech’s manufacturing site in Marburg, Germany, which increases the active substance manufacturing capacity by approximately 410 million doses in 2021.
